Press Releases

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

September 12, 2023

In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were enrolled and treated with OVYDSO™ (Olgotrelvir) or placebo.

Abivertinib Shows Promise Treating Marginal Zone Lymphoma

July 13, 2023

Abivertinib (Fujovee; Sorrento Therapeutics), an irreversible Bruton tyrosine kinase (BTK) inhibitor, produced promising results in patients with relapsed/refractory marginal zone lymphoma (MZL) in a recent phase 2a trial (NCT03060850).

Abivertinib Produces Responses in Relapsed/Refractory Marginal Zone Lymphoma 

July 5, 2023

Treatment with the irreversible BTK inhibitor abivertinib (Fujovee) led to responses and disease control in patients with relapsed/refractory marginal zone lymphoma (MZL), according to data from a phase 2a trial (NCT03060850) conducted in China.

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

July 19, 2022

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function